Tibet Aim Pharm (SZSE:002826) Capex-to-Operating-Income : 0.14 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Tibet Aim Pharm's Capital Expenditure for the three months ended in Mar. 2024 was ¥-4.51 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥32.64 Mil.

Hence, Tibet Aim Pharm's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.14.

Tibet Aim Pharm Capex-to-Operating-Income Historical Data

The historical data trend for Tibet Aim Pharm's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm Capex-to-Operating-Income Chart

Tibet Aim Pharm Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Capex-to-Operating-Income

Get a 7-Day Free Trial

2.71

3.60

0.85

0.59

0.06

Tibet Aim Pharm Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Operating-Income	Get a 7-Day Free Trial															0.03	0.07	0.05	0.39	0.14

Competitive Comparison of Tibet Aim Pharm's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tibet Aim Pharm's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's Capex-to-Operating-Income falls into.

Tibet Aim Pharm Capex-to-Operating-Income Calculation

Tibet Aim Pharm's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2022 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-3.198)	/	56.159
	=	0.06

Tibet Aim Pharm's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-4.508)	/	32.638
	=	0.14

Tibet Aim Pharm (SZSE:002826) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Tibet Aim Pharm Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Tibet Aim Pharm (SZSE:002826) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » Capex-to-Operating-Income

Traded in Other Exchanges

N/A

Address

No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000

Website

http://www.emyy.cn

Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.

Executives

Peng Hui	Director
Pang Guo Qiang	Directors, executives
Li Qian Jin	Securities Affairs Representative
Liu Hang	Supervisors

Tibet Aim Pharm (SZSE:002826) Headlines

No Headlines